Anti-Rheumatic Drugs - Eastern Africa

The Anti-Rheumatic Drugs market in Eastern Africa is expected to witness significant growth in the coming years.
According to projections, the revenue in this market is anticipated to reach US$45.10m by 2024.
Furthermore, it is expected to exhibit a compound annual growth rate (CAGR) of 1.22% from 2024 to 2029, resulting in a market volume of US$47.92m by the end of 2029.
When compared globally, United States is predicted to generate the highest revenue in this market, amounting to US$34.70bn in 2024.
Eastern African countries are witnessing a growing demand for anti-rheumatic drugs due to a rise in rheumatoid arthritis cases.

Definition:
The market Anti-Rheumatic Drugs includes medication for the treatment of the inflammatory disease rheumatism. Due to the high prevalence of rheumatism and the large size of the market, this section of immune diseases is treated as a separate market. Both steroidal and non-steroidal anti-rheumatics are included. Disease-modifying rheumatic drugs (DMARDs), such as tumor necrosis factor inhibitors (a type of biologic DMARD), are particularly important in terms of commerciality.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: AbbVie, Johnson & Johnson, Pfizer, Amgen, Roche

Drugs to treat rheumatism
Steroidal (corticosteroids) and non-steroidal anti-rheumatics
Disease-modifying antirheumatic drugs (DMARDs)
Tumor necrosis factor (TNF) inhibitors

Drugs to treat other autoimmune diseases (such as multiple sclerosis or psoriasis)
Analgetics for general use (such as paracetamol)
Treatment of osteoarthritis

The demand for Anti-Rheumatic Drugs in Eastern Africa has been on the rise in recent years.

Customer preferences: Patients in Eastern Africa are increasingly seeking out Anti-Rheumatic Drugs due to the high prevalence of rheumatoid arthritis in the region. This has led to a growing demand for drugs that can alleviate the symptoms of the disease, such as pain, stiffness, and swelling.

Trends in the market: One of the key trends in the Anti-Rheumatic Drugs market in Eastern Africa is the growing popularity of biologic drugs. These drugs are highly effective in treating rheumatoid arthritis and have fewer side effects compared to traditional disease-modifying antirheumatic drugs (DMARDs). As a result, more patients are opting for biologic drugs, which has led to an increase in their availability in the region.Another trend in the market is the rise of generic drugs. With the increasing cost of healthcare in the region, many patients are unable to afford expensive branded drugs. Generic drugs offer a more affordable alternative, and as a result, their demand has been on the rise in recent years.

Local special circumstances: One of the challenges facing the Anti-Rheumatic Drugs market in Eastern Africa is the lack of adequate healthcare infrastructure in the region. Many patients are unable to access the drugs they need due to a shortage of healthcare facilities and trained healthcare professionals. This has led to a growing need for investment in healthcare infrastructure to improve access to drugs and treatment.

Underlying macroeconomic factors: The Anti-Rheumatic Drugs market in Eastern Africa is also influenced by broader macroeconomic factors such as economic growth and government healthcare policies. As the region continues to experience economic growth, more people are able to afford healthcare, which has led to an increase in demand for Anti-Rheumatic Drugs. Additionally, government policies aimed at improving access to healthcare have also contributed to the growth of the market. However, challenges such as corruption and political instability continue to hinder the growth of the market in some countries in the region.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.